CURRICULUM VITAE
CLIFFORD DEAN WRIGHT
RespirPharm Solutions
912 259th Court NE
Sammamish, WA 98074
Phone: (425) 802-5975
E-mail: cwright.respirpharmsolutions@gmail.com
Home:
912 259th Court NE
Sammamish, WA 98074
Phone: (425) 868-4845
wrightathome2001@aol.com
ACADEMIC TRAINING
Ph.D., Microbiology, August 1983, University of Minnesota, Minneapolis, Minnesota.
Minor in Biochemistry. Emphasis on neutrophil-mediated host defense.
M.S., Microbiology, August 1979, Brigham Young University, Provo, Utah.
Minor in Biochemistry. Emphasis on immunochemistry of antibody-antigen interactions.
B.S., Microbiology, December 1977, Brigham Young University, Provo, Utah.
Minors in Chemistry and Zoology. Emphasis on immunology. Graduated cum laude with
highest honors.
PROFESSIONAL HISTORY
April 2012 to Present
RespirPharm Solutions
Sammamish, Washington 98074
PRINCIPAL. Consultant in drug discovery with small molecule and protein-based
therapeutic modalities. Extensive experience with in vitro and in vivo pharmacology in
asthma, chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary
fibrosis. Additional broad background in inflammatory and autoimmune disease
therapeutic areas. Role in pharmaceutical matrix management with both line project
leadership experience as well as management of industry and academic collaborative
research.
October 2007 to March 2012
Respiratory Therapeutics Research
Gilead Science Inc.
Seattle, Washington 98102
SENIOR DIRECTOR. Leader of Respiratory Biology Group charged with identification
and characterization of novel therapeutics for respiratory disorders, including: asthma;
chronic obstructive pulmonary disease; idiopathic pulmonary fibrosis; and cystic fibrosis.
Responsible for expansion of Seattle research beyond five scientists focused on antimicrobial agents to a group of nineteen scientists, providing in vitro pharmacology
(biochemical, cellular, and immunopharmacology), in vivo pharmacology, bioanalytical,
and bioinformatics capabilities. Therapeutic approaches include targets in both innate and
acquired immune-mediated mechanisms associated with airway pathophysiology.
Research projects include LABA-steroid mutual prodrugs, bi-functional 2 adrenergic
agonists-phosphodiesterase 4 inhibitors, endothelin antagonists, macrolides, protein
kinase-mediated signal transduction, and caspase inhibitors. Team leader of drug
discovery teams for pulmonary therapeutics, including mutual pro-drug project. Member
of Joint Steering Committee managing collaboration with Parion Sciences to discover and
develop novel ENaC channel blockers. Manager of interactions with contract research
organizations and academic institutions to expedite compound evaluation and
translational assessment of candidate molecules. Member of cross-site teams for
assessment of potential respiratory clinical utilities of agents from various Gilead
Sciences therapeutic areas. Member of business development team responsible for
evaluation and due diligence of opportunities related to respiratory and inflammatory
diseases.
January 2007 to October 2007
Department of Inflammation Research
Amgen Inc.
Seattle, Washington 98119
DIRECTOR RESEARCH. Leader of laboratory to identify and prosecute on neutrophil
targets as inflammation therapeutics. Team leader of serine protease project to develop
novel therapeutics for asthma and inflammatory airway disorders. Responsible for
assessment of Member of licensing team responsible for evaluation of opportunities
related to autoimmune and inflammatory diseases. Serve as Amgen Washington liaison to
facilitate cross-site decision making regarding licensing opportunities. Member of
Asthma Internal Advisory Board to assess strategy and opportunities related to pulmonary
drug discovery.
October 2003 to December 2006
Department of Immune Systems
Assay Technologies Group
Amgen Inc.
Seattle, Washington 98119
ASSOCIATE DIRECTOR. Leader of Assay Technologies Group. Responsible for
development, validation, and implementation of biochemical and cellular pharmacology
assays to support Inflammation Therapeutic Area at Amgen. Provide assay support for
small molecule, protein, and antibody therapeutics. The group was successful in
providing assay support to facilitate the timely progress of projects in the Amgen
Inflammation Therapeutic Area portfolio through discovery and development.
Assessment of acquired and innate immune mechanisms associated with inflammatory
disorders. Manager of Blood Purification Group, responsible for providing purified
human cells to researchers at different Amgen sites. Member of cross-site high
throughput screening council. Member of licensing team responsible for evaluation of
opportunities related to autoimmune and inflammatory diseases. Member of Asthma
Internal Advisory Board to assess strategy and opportunities related to pulmonary drug
discovery.
July 2001 to October 2003
Department of Inflammation Research
Amgen Inc.
Thousand Oaks, California 91320
RESEARCH SCIENTIST V. Co-leader of drug discovery team focused on discovery and
characterization of medicinal chemistry-based inhibitors of p38 mitogen-activated protein
kinase. Successfully progressed inhibitors to human clinical trials in arthritis. Served on
clinical research team, supporting regulatory functions related to clinical evaluation of the
anti-inflammatory properties of p38 inhibitors. Member of licensing team responsible
for evaluation of opportunities related to autoimmune and inflammatory diseases.
Member of Institutional Animal Care and Use Committee. Head of biochemical/cellular
pharmacology laboratory supporting target identification and drug discovery efforts
relating to inflammation, autoimmunity, and pain. Efforts of laboratory focused on
identification and characterization of novel inhibitors stimulus/response coupling in
inflammatory cells.
August 2000 to June 2001
Department of Pharmacology/Pathology
Amgen Inc.
Thousand Oaks, California 91320
RESEARCH SCIENTIST V. Leader of clinical research team evaluating the efficacy of
secretory leukocyte protease inhibitor in a Phase I/II asthma clinical trial. As a member
of a cardiovascular clinical research project team, characterized the biochemical
mechanism of a novel acting thrombolytic agent (alfimeprase) as well as its effect on
synthesis and metabolism of bradykinin. Member of a clinical research team evaluating a
novel protein-based cytokine inhibitor as a therapeutic agent for arthritis. Member of
drug discovery team focused on identification and characterization of medicinal
chemistry-based inhibitors of inflammatory cytokine production. Member of licensing
team evaluating opportunities related to autoimmune and inflammatory diseases. Member
of Institutional Animal Care and Use Committee. Head of biochemical/cellular
pharmacology laboratory supporting drug discovery efforts relating to inflammation,
autoimmunity and cardiovascular disorders. Coordinator of academic collaborations in
the area of inflammatory pulmonary diseases.
September 1998 to August 2000
Pharmacology Department
Amgen Inc.
Thousand Oaks, California 91320
RESEARCH SCIENTIST III. Leader of asthma preclinical research team. Member of
clinical research project team to evaluate novel thrombolytic agents. Head of
biochemical/cellular pharmacology laboratory supporting drug discovery efforts relating
to inflammation, autoimmunity and cardiovascular disorders. Member of licensing team
evaluating opportunities relating to autoimmune and inflammatory diseases. Coordinator
of academic collaborations in the area of inflammatory pulmonary diseases.
May 1995 to September 1998
Inflammation Research Department
Amgen Inc.
Boulder, Colorado 80301
RESEARCH SCIENTIST III. Team Leader of the Proteases in Pulmonary Diseases
Project Team. Coordinated efforts of multidisciplinary team located in Boulder, CO and
Thousand Oaks, CA in the discovery of novel anti-asthma agents. Responsible for
evaluation of secretory leukocyte protease inhibitor (SLPI) as an asthma therapeutic and
compilation of pre-IND package. Directed drug discovery effort focused on identification
of medicinal chemistry-based inhibitors of mast cell tryptase as asthma therapeutics.
Lead effort to evaluate the role of matrix metalloproteinases in the pathogenesis of
chronic obstructive pulmonary disorders. Coordinator of academic collaborations in the
area of inflammatory pulmonary diseases.
March 1994 to May 1995
Inflammation Research Department
Amgen Inc.
Thousand Oaks, California 91320
RESEARCH SCIENTIST III. Team Leader of Endothelial Cell/Macrophage Activation
Team focused on the development of inhibitors of inflammatory cytokine production.
Directed drug discovery effort focused on identification of medicinal chemistry-based
inhibitors of p38 MAP kinase and TNF alpha convertase. Key participant in start-up of
Amgen inflammation research and medicinal chemistry-based drug discovery.
Laboratory provided cell biology, molecular biology, biochemical, and biophysical
support to anti-inflammatory drug discovery. Responsible for administration of academic
collaborations relating to inflammation projects.
April 1990 to March 1994
Immunopathology Department
Parke-Davis Pharmaceutical Research
Warner-Lambert Company
Ann Arbor, Michigan 48105
SENIOR RESEARCH ASSOCIATE. Responsible for research program to examine the
role of polymorphonuclear leukocytes in arthritis and inflammation. Laboratory provided
cell biology, molecular biology, biochemical, and biophysical support, relating to
arachidonic acid metabolism, leukocyte-endothelial cell interactions, signal transduction,
and oxygen radical generation. Responsible for administration of grants with academic
collaborators relating to cell adhesion project. Member of the Arthritis/Inflammation and
Myocardial Ischemia Team. Chair and founder of the Leukocyte-Endothelial Cell
Adhesion project.
January 1989 to April 1990
Pharmacology Department
Parke-Davis Pharmaceutical Research Division
Warner-Lambert Company
Ann Arbor, Michigan 48105
RESEARCH ASSOCIATE. Responsible for research program to examine the role of
polymorphonuclear leukocytes in arthritis and inflammation. Responsible for providing
support in cell biology and biochemistry to the drug discovery strategy. Research
program identified novel inhibitors of inflammatory cell signal transduction and 5lipoxygenase. Member of the Arthritis/Inflammation and Analgesia Drug Discovery
Teams.
July 1988 to December 1988
Biological Research
Goedecke Research Institute
D-7800 Freiburg
Federal Republic of Germany
RESEARCH ASSOCIATE. Participant in the initial exchange program between ParkeDavis in Ann Arbor and Goedecke, its affiliate in the Federal Republic of Germany.
Gained significant international experience in drug discovery and interactions with
German academic laboratories. Research program identified and characterized the
generation of nitric oxide by human neutrophils.
May 1987 to June 1988
Pharmacology Department
Parke-Davis Pharmaceutical Research Division
Warner-Lambert Company
Ann Arbor, Michigan 48105
RESEARCH ASSOCIATE. Responsible for research program to examine the role of
polymorphonuclear leukocytes in asthma and allergy. Research program involved the
study of stimulus-response coupling in human neutrophils to evaluate sites of therapeutic
intervention in cell activation. Research included investigation of eosinophils and
macrophages. Responsible for providing biochemical support to respiratory/allergy
group. Member of the Respiratory/Allergy, Arachidonic Acid, and Bradykinin Project
Teams. Member, Pharmacology Department Seminar Committee. Member, Biochemistry
Discussion Group.
December 1984 to May 1987
Pharmacology Department
Parke-Davis Pharmaceutical Research Division
Warner-Lambert Company
Ann Arbor, Michigan 48105
SENIOR SCIENTIST. Responsible for research program to examine the role of
polymorphonuclear leukocytes in asthma and allergy. Research program involved the
study of stimulus-response coupling in human neutrophils to evaluate sites of therapeutic
intervention in cell activation. Responsible for providing biochemical support to
respiratory/allergy group. Member of the Respiratory/Allergy, Arachidonic Acid, and
Migraine Project Teams. Member, Pharmacology Department seminar committee. Cochairman, Cardiovascular-Immunopharmacology Discussion Group.
September 1983 to December 1984
Pharmacology Department
Parke-Davis Pharmaceutical Research Division
Warner-Lambert Company
Ann Arbor, Michigan 48105
SCIENTIST. Responsible for establishment of a research program to examine the role of
polymorphonuclear leukocytes in asthma and allergy. Participation in drug design and
development in Immunopharmacology Section. Co-chairman, CardiovascularImmunopharmacology Discussion Group.
September 1979 to August 1983
Department of Microbiology
University of Minnesota
Minneapolis, Minnesota 55455
RESEARCH ASSISTANT. Performed research toward completion of doctoral degree.
Research investigated polymorphonuclear leukocyte functions and their modulation by
yeast cell wall polysaccharides. Research involved studies of bioorganic chemistry of
carbohydrates. Teaching responsibility for immunology and microbiology laboratories.
December 1977 to August 1979
Department of Microbiology
Brigham Young University
Provo, Utah 84602
RESEARCH AND TEACHING ASSISTANT. Performed research toward completion of
M.S. degree. Research included preparation and purification of rabbit antisera for use in
studies of antibody-antigen interaction using [13C] NMR. Teaching responsibility for
immunology and microbiology laboratories.
January 1977 to July 1977
Department of Chemistry
Brigham Young University
Provo, Utah 84602
RESEARCHER. Performed research project for completion of requirements of B.S.
honors degree. Research involved studying the effect of ionic strength on pKa’s of
titrated ion exchange material.
ACADEMIC POSITIONS
1991-1994
Adjunct Professor
Biology Department
Eastern Michigan University
Ypsilanti, Michigan 48197
1991-1994
Mentor
Student Biomedical Research and Women in Science Programs
University of Michigan
Ann Arbor, Michigan 48109
MEETING ORGANIZATION
Vascular Biology: Adhesion Molecules and Gene Expression
University of Michigan, 2 May 1991
PERSONAL RECOGNITION
Eli Lilly Predoctoral Fellowship, 1981 to 1983
University of Minnesota Graduate School Fellowship, 1979 to 1980
Brigham Young University Department of Chemistry undergraduate research grant, 1977
Brigham Young University Undergraduate Scholarship, 1972 to 1973, 1976, 1977
LANGUAGE SKILLS
Portuguese
German
PROFESSIONAL MEMBERSHIP
American Association for Immunologists, Bethesda, Maryland
American Association for the Advancement of Science, Washington, D.C.
American Society for Microbiology, Washington, D.C.
Inflammation Research Association
The American Society for Cell Biology, Bethesda, Maryland
The Society for Leukocyte Biology, Bethesda, Maryland
CONSULTING REVIEWER
Agents and Actions
American Journal of Pathology
Arthritis and Rheumatism
Biochemical Pharmacology
Blood
Cellular Immunology
Clinical Immunology and Immunopathology
Drug Development Research
European Respiratory Journal
Haematologia
In Vitro Cellular & Developmental Biology-Animal
Journal of Cardiovascular Pharmacology
Journal of Clinical Immunology
Journal of Immunology
Journal of Leukocyte Biology
Life Sciences
Naunyn-Schiedeberg’s Archives of Pharmacology
GRANT REVIEW
1991-1994
Member, Research Grant-in-Aid Committee
American Heart Association of Michigan
BIBLIOGRAPHY
Books
1. Wright, C.D. Affinity adsorption of immune serum: Preparation of antibodies for
carbon-13 nuclear magnetic resonance studies. M.S. thesis, Brigham Young University,
1979.
2. Wright, C.D. Effect of solubilized yeast cell wall mannan on human neutrophil
functions: Inhibition of myeloperoxidase-mediated candidacidal activity. Ph.D. thesis,
University of Minnesota, 1983.
Articles
1. Wright, C.D., M. J. Herron, G. R. Gray, B. Holmes, and R. D. Nelson. Influence of
yeast mannan on human neutrophil functions: Inhibition of release of myeloperoxidase
related to carbohydrate-binding property of the enzyme. Infect. Immun. 1981; 32:731-38.
2. Wright, C.D., J. U. Bowie, G. R. Gray, and R. D. Nelson. Candidacidal activity of
myeloperoxidase: Mechanisms of inhibitory influence of soluble cell wall mannan.
Infect. Immun. 1983; 42:76-80.
3. Wright, C.D., J. U. Bowie, and R. D. Nelson. Influence of yeast mannan on release
of myeloperoxidase by human neutrophils: Determination of structural features of
mannan required for formation of myeloperoxidase-mannan-neutrophil complexes.
Infect. Immun. 1984; 43:467-71.
4. Wright, C.D., and R. D. Nelson. Candidacidal activity of myeloperoxidase:
therapeutic influence of the enzyme in vivo. Infect. Immun. 1985; 47:363-65.
5. Wright, C.D., and M. D. Hoffman. The protein kinase C inhibitors H-7 and H-9 fail
to inhibit human neutrophil activation. Biochem. Biophys. Res. Commun. 1986;
135:749-755.
6. Wright, C.D., and M. D. Hoffman. Comparison of the roles of calmodulin and
protein kinase C in activation of the human neutrophil respiratory burst. Biochem.
Biophys. Res. Commun. 1987; 142:53-62.
7. Thueson D.O., J. A. Kennedy, C. D. Wright, and M. C. Conroy. Specific inhibition
of phorbol ester and DiC8-induced histamine release from human basophils by the
protein kinase C inhibitors, H-7 and H-9. Biochem. Biophys. Res. Commun. 1987;
144:732-40.
8. Wright, C.D., M. D. Hoffman, D. O. Thueson, and M. C. Conroy. Inhibitor of human
neutrophil activation by the allergic mediator release inhibitor, CI-922. Differential
inhibition of responses to a variety of stimuli. J. Leuk. Biol. 1987; 42:30-35.
9. Wright, C.D., M. D. Hoffman, D. O. Thueson, and M. C. Conroy. Inhibition of
human neutrophil activation by the allergic mediator release inhibitor, CI-922:
Mechanism of inhibitory activity. Biochem. Biophys. Res. Commun. 1987; 148:1110-17.
10. Wright, C.D., and R. D. Nelson. Candidacidal activity of myeloperoxidase:
Characterization of myeloperoxidase-yeast complex formation. Biochem. Biophys. Res.
Commun. 1988; 154:809-17.
11. Wright, C.D., A. Mülsch, R. Busse, and H. Osswald. Generation of nitric oxide by
human neutrophils. Biochem. Biophys. Res. Commun. 1989; 160:813-19.
12. Wright, C.D., and J. E. Low. Formation of chloramine derivatives of histamine:
Role of histamine chloramines in bronchoconstriction. Biochem. Biophys. Res. Commun.
1989; 165:1018-26.
13. Wright, C.D., S. F. Stewart, P. J. Kuipers, M. D. Hoffman, D. O. Thueson, and M. C.
Conroy. Inhibition of human neutrophil activation by the allergic mediator release
inhibitor, CI-949: Mechanism of inhibitory activity. Biochem. Biophys. Res. Commun.
1990; 167:828-34.
14. Wright, C.D., P, J. Kuipers, D. Kobylarz-Singer, L. J. Devall, B. A. Klinkefus, and
R. E. Weishaar. Differential inhibition of human neutrophil functions: Role of cyclic
AMP-specific, cyclic GMP-insensitive phosphodiesterase. Biochem. Pharmacol. 1990;
40:699-707.
15. Wright, C.D., L. J. Devall, K. A. Aker, D. O. Thueson, and M. C. Conroy.
Differential regulation of the activation of human eosinophils, macrophages, and
neutrophils. Effect of the allergic mediator release inhibitor CI-949. Agents Actions
1990; 31:11-15.
16. Schrier, D.J., M. E. Lesch, C. D. Wright, and R. B. Gilbertsen. The antiinflammatory
effects of adenosine receptor agonists on the carrageenan-induced pleural inflammatory
response in rats. J. Immunol. 1990; 145:1874-79.
17. Conroy, M.C., J. A. Kennedy, J. C. Chestnut, C. D. Wright, R. L. Adolphson, and D.
O. Thueson. Inhibition of histamine, leukotriene C4/D4, and thromboxane B2 release
from human basophils and human chopped lung mast cells by the allergic mediator
release inhibitor, CI-949. J. Allergy Clin. Immunol. 1990; 86:902-08.
18. Wright, C.D., S. F, Stewart, P. J. Kuipers, M. D. Hoffman, D. O. Thueson, and M. C.
Conroy. Inhibition of human neutrophil activation by the allergic mediator release
inhibitor, CI-949. J. Leuk. Biol. 1991; 49:58-64.
19. Connor, C.D., W. A. Cetenko, M. D. Mullican, R. J. Sorenson, P. C. Unangst, R. J.
Weikert, R. L. Adolphson, J. A. Kennedy, D. O. Thueson, C. D. Wright, and M. C.
Conroy. Novel benzothiophene, benzofuran and naphthalene carboxamidotetrazoles as
potent antiallergy agents. J. Med. Chem. 1992; 35:958-65.
20. Wright, C.D., L. J. Devall, K. A. Aker, D. O. Thueson, and M. C. Conroy.
Differential regulation of human eosinophil, macrophage, and neutrophil functions by the
allergic mediator release inhibitor CI-959. Agents Actions 1992; 36:11-16.
21. Boschelli, D.H., D. T. Connor, P. J. Kuipers, and C. D. Wright. Synthesis and
cyclooxygenase and 5-lipoxygenase inhibitory activity of some thiazolidene-4-one
analogs of meclofenamic acid. Bioorg. Med. Chem. Letters 1992; 2:705-708.
22. Burke, S.E., C. D. Wright, R. E. Potoczak, D. M. Boucher, G. D. Dodd, D. G. Taylor,
Jr., and H. R. Kaplan. Reduction of canine myocardial infarct size by CI-959 an inhibitor
of inflammatory cell activator. J. Cardiovasc. Pharmacol. 1992; 20:619-629.
23. Kramer, J.B., D. H. Boschelli, D. T. Connor, C. R. Kostlan, D. L. Flynn, R. D. Dyer,
D. A. Bornemeier, J. A. Kennedy, C. D. Wright, P. J. Kuipers. Synthesis of reversed
hydroxamic acids of indomethacin: Dual inhibitors of cyclooxygenase and 5lipoxygenase. Bioorg. Med. Chem. Letters 1992; 12:1655-1660.
24. Boschelli, D.H., D.T. Connor, D.A. Bornemeier, R.D. Dyer, J.A. Kennedy, P.J.
Kuipers, G.C. Okonkwo, D.J. Schrier, and C.D. Wright. 1,3,4-Oxadiazole, 1,3,4thiadiazole, and 1,2,4-triazole analogs of the fenamates: in vitro inhibition of
cyclooxygenase and 5-lipoxygenase activities. J. Med. Chem. 1993; 36:1802-1810.
25. Unangst, P.C., D.T. Connor, W.A. Cetenko, R.J. Sorenson, J.C. Sircar, C.D. Wright,
D.J. Schrier, and R.D. Dyer. Oxazole, thiazole and imidazole derivatives of 2,6-di-tertbutylphenol as dual 5-lipoxygenase and cyclooxygenase inhibitors. Bioorg. Med Chem.
Letters 1993; 3:1729-1734.
26. Kramer, J.B., D.H. Boschelli, D.T. Connor, C.R. Kostlan, P.J. Kuipers, J.A.
Kennedy, C.D. Wright, D.A. Bornemeier, and R.D. Dyer. Cyclooxygenase and 5lipoxygenase inhibitory activity of 2,6-di-t-butylphenols linked by a sulfur atom to
1,3,4-thiadiazoles and 1,3,4-oxadiazoles. Bioorg. Med. Chem. Letters 1993; 3:2827-2830.
27. Unangst, P.C., D.T. Connor, W.A. Cetenko, R.J. Sorenson, C.R. Kostlan, J.C. Sircar,
C.D. Wright, D.J. Schrier, and R.D. Dyer. Synthesis and biological evaluation of 5- [3,5bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-oxazoles,-thiazoles, and
-imidazoles: novel dual 5-lipoxygenase and cyclooxygenase inhibitors with
antiinflammatory activity. J. Med. Chem. 1994; 37:322-328.
28. Boschelli, D.H., J. B. Kramer, D. T. Connor, M. E. Lesch, D. J. Schrier, M. A. Ferin,
and C. D. Wright. 3-Alkoxy-benzo[b]thiophene-2-carboxamides as inhibitors of
neutrophil-endothelial cell adhesion. J. Med. Chem. 1994; 37:717-718.
29. Wright, C.D., S. F. Stewart, P. J. Kuipers, M. D. Hoffman, L. J. Devall, J. A.
Kennedy, M. A. Ferin, D. O. Thueson, and M. C. Conroy. Selective regulation of human
neutrophil functions by the cell activation inhibitor CI-959. J. Leuk. Biol. 1994; 55:443451.
30. Wiles, M.E., J.A. Dykens, and C.D. Wright. Regulation of polymorphonuclear
leukocyte membrane fluidity: effect of cytoskeletal modification. J. Leuk. Biol. 1994;
56:192-199.
31. Wright, C.D., W.L. Cody, J.B. Dunbar, Jr., A.M. Doherty, G.P. Hingorani, and S. T.
Rapundalo. Characterization of endothelins as chemoattractants for human neutrophils.
Life Sciences 1994; 55:1633-1641.
32. Wright, C.D., J.A. Kennedy, P.J. Kuipers, and M.A. Ferin. Stimulus-specific effects
of CI-986 on arachidonic acid metabolism by human neutrophils. Inflamm. Res. 1995;
44:74-78.
33. Kramer, J.B., T. Capiris, J.D. Sircar, D.T. Connor, D.A. Bornemeier, R.D. Dyer, P.J.
Kuipers, J.A. Kennedy, C.D. Wright, G.C.N. Okonkwo, M.E. Lesch, D.J. Schrier, and
D.H. Boschelli. Hydroxylamine analogs of 2,6 di-t-butylphenols: dual inhibitors of
cyclooxygenase and 5-lipoxygenase or selective 5-lipoxygenase inhibitors. Bioorg. Med.
Chem. 1995; 3:403-410.
34. Wiles, M.E., J.A. Dykens, and C.D. Wright. Human neutrophil (PMN) oxygen
radical production and the cytoskeleton. Life Sciences 1995; 57:1533-1546.
35. Boschelli, D.H., J.B. Kramer, S.S. Khatana, R.J. Sorenson, D.T. Connor, M.A. Ferin,
C.D. Wright, M.E. Lesch, K. Imre, G.C. Okonkwo, D.J. Schrier, M. C. Conroy, E.
Ferguson, J. Woelle, and U. Saxena. Inhibition of E-selectin-, ICAM-1-, and VCAM-1mediated cell adhesion by benzo[b]thiophene-, benzofuran-, indole-, and naphthalene-2carboxamides: identification of PD 144795 as an antiinflammatory agent. J. Med. Chem.
1995; 38:4597-4614.
36. Zitnik, R.J., J. Zhang, M.A. Kashem, T. Kohno, D.E. Lyons, C.D. Wright, E. Rosen,
I. Goldberg, A.C. Hayday. The cloning and characterization of a murine secretory
leukocyte protease inhibitor cDNA. Biochem. Biophys, Res. Commun. 1997; 232:687697.
37. Gaudino, J.J., K. Bjergarde, P-Y. Chan-Hui, C.D. Wright, and D.S. Thomson.
Synthesis of novel fluorescently labeled sphingomyelin derivatives useful for
sphingomyelinase assay. Bioorg. Med. Chem. Letters 1997; 7:1127-1132.
38. Hartsel, S.A., C. Chen, J. Kennedy, A. Bendele, C. Wright, and W.S. Marshall. Antiinflammatory activity of purine nucleoside analogs. Nucleosides Nucleotides 1997;
16:1291-1294.
39. Fath, M.A., X. Xu, R.E. Hileman, R.J. Linhardt, M.A. Kashem, R.M. Nelson,
Wright, C.D. and W.A. Abraham. Characterization of the interaction of secretory
leukocyte protease inhibitor with heparin: potential impact on therapeutic utility. J. Biol.
Chem. 1998; 273:13563-13569.
40. Barrios, V.E., S.C. Middleton, C. F. Toombs, A. M. Havill and C. D. Wright.
Tryptase mediates hyperresponsiveness in isolated guinea pig bronchi. Life Sciences
1998; 63:2295-2303.
41. Wright, C.D., J.A. Kennedy, R.J. Zitnik, and M.A. Kashem. Inhibition of murine
neutrophil proteinases by human and murine secretory leukocyte protease inhibitor.
Biochem. Biophys. Res. Commun. 1999; 254:614-617.
42. Wright, C.D., A.M. Havill, S.C. Middleton, M.A. Kashem, P.A. Lee, D.J. Dripps,
T.G. O’Riordan, M.P. Bevilacqua, and W.M. Abraham. Inhibition of allergen-induced
pulmonary responses by secretory leukocyte protease inhibitor. J. Pharmacol. Exp.
Therap. 1999; 289:1007-1014.
43. Burgess, L.E., B.J. Newhouse, P. Ibrahim, J. Rizzi, M.A. Kashem, A. Hartman, B.J.
Brandhuber, C.D. Wright, D.S. Thomson. G.P.A. Vigers, and K. Koch. Potent, selective,
non-peptidic inhibitors of human lung tryptase. Proc. Natl. Acad. Sci. USA. 1999,
96:8348-8352.
45. Wright, C.D., A.M. Havill, S.C. Middleton, M.A. Kashem, W.M. Abraham, D.S.
Thomson, and L.E. Burgess. Inhibition of allergen-induced pulmonary responses by the
tryptase inhibitor AMG-126737. Biochem. Pharmacol. 1999, 58:1989-1996.
46. Mulligan, M.S., A.B. Lentsch, M. Huber-Lang, R-F. Guo, V. Sarma, C.D. Wright,
T.R. Ulich, and P.A. Ward. Anti-inflammatory effects of mutant forms of secretory
leukocyte protease inhibitor. Am. J. Pathol. 2000, 156:1033-1039.
47. Grobmyer, S.R., P.S. Barie, C.F. Nathan, M. Fuortes, E. Lin, S.F. Lowry, C.D.
Wright, M.J. Weyant, L. Hydo, F. Reeves, M.U. Shiloh, and A. Ding. Secretory
leukocyte protease inhibitor, an inhibitor of neutrophil activation, is elevated in serum in
human sepsis and experimental endotoxemia. Crit. Care Med. 2000, 28:1276-1282.
48. Zhu, J., C. Nathan, W. Jin, D. Sim, G.S. Ashcroft, S.M. Wahl, L. Lacomis, H.
Erdjument-Bromage, P. Tempest, C.D. Wright, and A. Ding. Conversion of proepithelin
to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell 2002,
111:867-878.
49. Barrios, V.E., M.A. Jarosinski, and C.D. Wright. Proteinase-activated receptor-2
mediates airway hyperresponsiveness in isolated guinea pig bronchi. Biochem.
Pharmacol. 2003, 66:515-521.
50. Brown, M.E., J.N. Fitzner, T. Stevens, W. Chin, C.D. Wright, and J.P. Boyce.
Salicylanilides: selective inhibitors of interleukin-12p40 production. Bioorg. Med.
Chem. 2008, 16:8760-8764.
51. Boyce, J.P., M.E. Brown, W. Chin, J.N. Fitzner, R.J. Paxton, M. Shen, T. Stevens,
M.F. Wolfson, and C.D. Wright. Identification of 14-3-3 by chemical affinity with
salicylanilide inhibitors of interleukin-12p40 production. Biocong. Chem. 2008, 19:17751784.
52. Tannheimer, S.L, E.A. Sorensen, A.C.. Haran, C.N. Mansfield, C. D. Wright, and M.
Salmon. Additive anti-inflammatory effects of beta 2 adrenoceptor agonists or
glucocorticosteroid with roflumilast in human peripheral blood mononuclear
cells. Pulm. Pharmacol. Ther. 2012; 25:178-184.
53. Tannheimer, S.L, C.D. Wright, and M. Salmon. Combination of roflumilast with a
Beta-2 Adrenergic Receptor Agonist Inhibits proinflammatory and profibrotic mediator
release from human lung fibroblasts. Respir. Res. 2012, accepted with revisions.
Book Chapters and Reviews
1. Weishaar, R.E., D. Kobylarz-Singer, J. A. Keiser, C. D. Wright, J. Cornicelli, and R.
Panek. Cyclic nucleotide phosphodiesterases in the circulatory system: Biochemical,
pharmacological, and functional characteristics, p. 249-269. In: S. J. Strada and H.
Hidaka (eds). The Biology of Cyclic Nucleotide Phosphodiesterases (Advances in
Second Messenger and Phosphoprotein Research, vol. 25). Raven Press, New York,
1992.
2. Boschelli D. H., and C. D. Wright. Inhibitors of leukocyte-endothelial cell
interactions as anti-inflammatory therapeutics. Current Drugs 1993; 2:723-735.
3. Wright, C.D. Protease Inhibitors as a New Therapeutic Approach in Bronchial
Asthma. Syllabus for scientific workshop entitled “Proteases in Allergic Airways
Disease”. 57th Annual Meeting of the American Academy of Asthma, Allergy, &
Immunology, March 16-21, 2001.
4. Wright, C.D. Secretory leukocyte protease inhibitor: pharmacokinetic and
pharmacodynamic implications for lung delivery. Syllabus for scientific workshop
entitled “Pulmonary Delivery and Disposition of Inhaled Aerosols”. 28th International
Symposium on Controlled Release of Bioactive Materials, June 23-27, 2001.
Patents
1. Boschelli D. H., D.T. Connor, C.D. Wright. 3-Alkyloxy-, aryloxy-, or arylalkyloxybenzo(b)thiophene-2-carboxamides as inhibitors of cell adhesion. US5208253 (1993).
2. Boschelli D. H., D.T. Connor, C.D. Wright. 3-Alkyloxy-, aryloxy-, or arylalkyloxybenzo(b)thiophene-2-carboxamides as inhibitors of cell adhesion. EU93906217 (1993).
3. Boschelli D. H., D.T. Connor, C.D. Wright. 3-Alkyloxy-, aryloxy-, or arylalkyloxy
benzo(b)thiophene-2-carboxamides as inhibitors of cell adhesion. US5356926 (1994).
4. Boschelli D. H., D.T. Connor, C.D. Wright. 3-Alkyloxy-, aryloxy-, or arylalkyloxybenzo(b)thiophene-2-carboxamides as inhibitors of cell adhesion. EP0628038B1 (1999).
5. Niven R.W., C.D. Wright, B.S. Chang. Secretory leukocyte protease inhibitor dry
powder pharmaceutical compositions. WO 99/17800.
6. Niven R.W., C.D. Wright, B.S. Chang. Secretory leukocyte protease inhibitor dry
powder pharmaceutical compositions. EP1030683A1 (2000).
7. Wright, C.D., and V.E. Barrios. Inhibitors of protease-activated receptor-2 (PAR-2)
as novel asthma therapeutics. WO 01/52883A1 (2001).
8. Niven R.W., C.D. Wright, B.S. Chang. Secretory leukocyte protease inhibitor dry
powder pharmaceutical compositions. US20020010318A1 (2002).
9. Boschelli D. H., D.T. Connor, C.D. Wright. 3-(1-Methylethoxy)benzo[b]thiophene-2carboxamides as inhibitors of cell adhesion. EP091666B1 (2003).
Invited Seminars
1. Workshop on Proteases in Allergic Airways Disease. “Protease Inhibitors as a New
Therapeutic Approach in Bronchial Asthma”. 57th annual meeting of the American
Academy of Asthma, Allergy & Immunology, 17 March 2001
2. Workshop on Pulmonary Delivery and Disposition of Inhaled Aerosols. “Secretory
leukocyte protease inhibitor: pharmacokinetic and pharmacodynamic implications for
lung delivery”. 28th International Symposium on Controlled Release of Bioactive
Materials, 24 June 2001
3. Pulmonary Research Group Symposium on Mast Cell Tryptase Inhibitors and Airway
Diseases. “Protease Inhibitors as a New Therapeutic Approach in Bronchial Asthma”
Johns Hopkins University, 26 June 2001
Abstracts
1. Wright, C. D., M. J. Herron, G. R. Gray, B. Holmes, and R. D. Nelson. Influence of
yeast mannan on human neutrophil functions: Inhibition of release of myeloperoxidase
related to lectin property of the enzyme. American Society for Microbiology, 1981, D29,
p. 48.
2. Wright, C. D., G. R. Gray, and R. D. Nelson. Influence of yeast mannan release of
myeloperoxidase (MPO) by human neutrophils (PMN). Determination of structural
features of mannan required for formation of the MPO-mannan-PMN complex.
American Society for Microbiology, 1982, D74, p. 59.
3. Wright, C. D., G. R. Gray, and R. D. Nelson. Inhibition of myeloperoxidasemediated candidacidal activity by solubilized cell wall mannan. American Society for
Microbiology, 1983, D87, p, 73.
4. Wright, C. D., and R. D. Nelson. The role of myeloperoxidase (MPO)-yeast complex
formation in MPO-mediated candidacidal activity. Fed. Proc. 1983;42:984.
5. Wright, C. D., and R. D. Nelson. The role of myeloperoxidase-yeast complex
formation in myeloperoxidase-mediated candidacidal activity in vivo. Fed. Proc.
1984;43:1845.
6. Wright, C. D.. Effects of solubilized yeast cell wall mannan on human neutrophil
functions: inhibition of myeloperoxidase-mediated candidacidal activity. Dissertation
Abstracts International 44:3355-B.
7. Wright, C. D., and M. D. Hoffman. Inhibition of human neutrophil activation by the
allergic mediator release inhibitor, CI-922. Fed. Proc. 1985;44:583.
8. Wright, C. D., and M. D. Hoffman. The cyclic nucleotide-dependent protein kinase
and protein kinase C inhibitors H-7 and H-9 fail to Inhibit human neutrophil activation.
Fed. Proc. 1986;45:851.
9. Hoffman, M.D., and C. D. Wright. The mechanism of inhibition of human
neutrophil activation by the allergic mediator release inhibitor, CI-922. Fed. Proc.
1986;45:854.
10. Wright, C. D., and J. E. Low. Formation of chloramine derivatives of histamine: role
of histamine chloramine in bronchoconstriction. Fed. Proc. 1987;46:1041.
11. Kuipers, P.J., L. J. Devall, and C. D. Wright. The role of cyclic nucleotide
phosphodiesterases in human neutrophil activation: stimulus-specific regulation of the
respiratory burst. Fed. Proc. 1987;46:1038.
12. Cornicelli, J.A., L. J. Devall, C. S. Sekerke, S. D. Burrows, C. D. Wright, and R. S.
Newton. Neutrophil mediated modification of LDL: a role of myeloperoxidase. J. Cell
Biol. 1987;105:163a.
13. Wright, C.D., L. J. Devall, K. A. Aker, D. O. Thueson, and M. C. Conroy.
Comparison of the effects of the allergic mediator release Inhibitor CI-949 on the
respiratory burst of human eosinophils, macrophages, and neutrophils. J. Allergy Clin.
Immunol. 1988;81:205.
14. Adolphson, R.L., J. C. Chestnut, P. J. Kuipers, D. O. Thueson, C. D. Wright, and M.
C. Conroy. Inhibition of histamine, leukotriene C4/D4, and thromboxane release from
human and guinea pig lung by CI-949. J. Allergy Clin. Immunol. 1988;81:232.
15. Kuipers, P.J., D. O. Thueson, M. C. Conroy, and C. D. Wright. Covalent and noncovalent binding of sulfamethoxazole and penicillin to serum albumin. FASEB J.
1988;2:A1112.
16. Stewart, S.F., M. C. Conroy, and C. D. Wright. Inhibition of arachidonic acid
metabolism in human neutrophils by the allergic mediator release inhibitor, CI-949.
FASEB J. 1988;2:A1604.
17. Wright, C. D., P. J. Kuipers, M. D. Hoffman, D. O. Thueson, and M. C. Conroy.
Inhibition of human neutrophil activation by the allergic mediator release inhibitor, CI949. FASEB J. 1988;2:A1604.
18. Cornicelli, J.A., L. Devall, C. S. Sekerke, S. D. Burrows, C. D. Wright, and R. S.
Newton. HOCl interaction with LDL lysine residues stimulates cholesteryl ester
formation in macrophages. 8th International Symposium on Atherosclerosis 1988;160.
19. Wright, C. D., M. D. Hoffman, D. O. Thueson, and M. C. Conroy. Inhibition of
human neutrophil activation by the allergic mediator release inhibitor, CI-949:
Mechanism of inhibitory activity. J. Cell Biol. 1988;107:58a.
20. Wright, C. D., L. J. Devall, K. A. Aker, D. O. Thueson, and M. C. Conroy.
Differential regulation of the activation of human eosinophils, macrophages, and
neutrophils: effect of the anti-allergy drug CI-959 on cellular responses. J. Allergy Clin.
Immunol. 1989;83:206.
21. Wright, C. D., L. J. Devall, D. O. Thueson, and M. C. Conroy. Inhibition of the
human neutrophil respiratory burst by CI-959. Characterization of inhibitory activity.
FASEB J. 1989;3:A907.
22. Kuipers, P.J., M. D. Hoffman, D. O. Thueson, M. C. Conroy, and C. D. Wright.
Inhibition of human neutrophil activation by the novel anti-allergic agent, CI-959.
FASEB J. 1989;3:A908.
23. Stewart, S.F., D. O. Thueson, M. C. Conroy, C. D. Wright. Inhibition of human
neutrophil arachidonic acid metabolism by the anti-allergy compound, CI-959. FASEB J.
1989;3:A908.
24. Wright, C. D., D. T. Conner, P. C. Unangst, and M. C. Conroy. Inhibition of the
human neutrophil respiratory burst by a novel series of benzo[b]thiophenes: Structureactivity relationship. FASEB J. 1990;4:A494.
25. Kuipers, P.J., and C. D. Wright. Comparison of the effects of phosphodiesterase
inhibitors on cyclic AMP levels in f-met-leu-phe- and serum-opsonized zymosanstimulated human neutrophils. FASEB J. 1990;4:A1123.
26. Mullican, M.D., W. A. Cetenko, R. J. Sorenson, P. C. Unangst, R. J. Weikert, D. T.
Connor, J. A. Kennedy, D. O. Thueson, C. D. Wright, and M. C. Conroy. Novel
benzothiophene, benzofuran, and naphthalene carboxamidotetrazoles as potential
antiallergy agents. American Chemical Society, Division of Medicinal Chemistry, April
1990, MEDI #81.
27. Schrier, D.J., C. Wright, and M. C. Conroy. Inhibition of immune complex-mediated
inflammation by the novel cell activation Inhibitor, CI-959. International Congress on
Inflammation 1990;12.
28. Lesch, M.E., M. Ferin, C. D. Wright, D. J. Schrier. The effects of (R)-N-(1-methyl2-phenylethyl)adenosine(L-PIA), a standard A1 selective adenosine agonist on acute
models of inflammation and rat neutrophil function. Inflammation Research Association
1990;18.
29. Wright, C. D., L. J. Devall, and M. C. Conroy. Inhibition of the human neutrophil
respiratory burst by the cell activation inhibitor CI-959: Effect on intracellular
bactericidal activity. J. Cell. Biochem. 1991;15c:219.
30. Ferin, M.A., M. C. Conroy, and C. D. Wright. Inhibition of neutrophil adhesion to
TNF-stimulated human umbilical vein endothelial cells by CI-959. FASEB J.
1991;5:A526.
31. Wright, C. D., W. L. Cody, J. B. Dunbar, A. M. Doherty, and S. T. Rapundalo.
Characterization of the chemotactic activity of endothelins and peptide fragments for
human neutrophils. FASEB J. 1991;5:A637.
32. Kennedy, J.A., M. A. Ferin, P. J. Kuipers, and C. D. Wright. Stimulus-specific
effects of CI-986 on arachidonic acid metabolism by human neutrophils. FASEB J.
1991;5:A1721.
33. Wright, C. D., G. P. Hingorani, and S. T. Rapundalo. Characterization of the human
neutrophil receptor for endothelin-1. J. Leuk. Biol. 1991; Suppl 2:40.
34. Yian, E.H., M. Ferin, and C. Wright. Regulation of TNF-alpha stimulated human
umbilical vein endothelial cell adhesiveness for human neutrophils. The 37th Annual
University of Michigan Medical School Student Biomedical Research Forum, 1991.
35. Ewart, B.H., R. Terrell, C. D. Wright, J. C. Jennette, and R. J. Falk. Elucidation of
signal transduction pathways involved in anti-myeloperoxidase antibody (a-MPO)
stimulation of neutrophils (PMN). J. Am. Soc. Nephrol. 1991;2:539.
36. Kuipers, P.J., M. A. Ferin, and C. D. Wright. Effects of CI-987 on arachidonic acid
metabolism by human neutrophils. FASEB J. 1992;6:A1052.
37. Kennedy, J.A., D. O. Thueson, C. D. Wright, and M. C. Conroy. Inhibition of
histamine release from human basophils by CI-959, a novel inhibitor of cell activation.
FASEB J. 1992;6:A1055.
38. Ferin, M.A., M. C. Conroy, and C. D. Wright. Inhibition of neutrophil adhesion to
lipopolysaccharide-stimulated human umbilical vein endothelial cells by CI-959. FASEB
J. 1992;6:A1891.
39. Boschelli, D.H., D. T. Connor, D. A. Bornemeier, R. D. Dyer, P. J. Kuipers, and C.
D. Wright. Conversion of non-steroidal anti-inflammatory drugs into either dual
inhibitors of 5-lipoxygenase and cyclooxygenase or into selective inhibitors of 5lipoxygenase. American Chemical Society, Division of Medicinal Chemistry, April
1992, MEDI #123.
40. Capiris, T., J. C. Sircar, D. T. Connor, D. J. Schrier, and C. D. Wright. Synthesis and
cyclooxygenase/5-lipoxygenase activity of 3,5-di-tertiary-butyl-4-hydroxyphenyl
heterocyclic ketones and their oximes. American Chemical Society, Division of
Medicinal Chemistry, August 1992, MEDI #107.
41. Dyer, R.D., D. A. Bornemeier, W. A. Cetenko, M. A. Ferin, P. J. Kuipers, M. E.
Lesch, D. J. Schrier, J. C. Sircar, and C. D. Wright. Biochemical pharmacology of
PD 136095, a novel inhibitor of arachidonic acid metabolism. 6th Intl. Conference
Inflammation Research Association 1992;P105.
42. Schrier, D.J., W. W. Cetenko, R. D. Dyer, S. Kuchera, K. Imre, M. E. Lesch, G. C.
N. Okonkwo, J. C. Sircar, C. Wright, and M. C. Conroy. The antiinflammatory and
analgesic effects of (Z)-5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]2imino-4-thiazolidinone (PD 136095), a novel dual inhibitor of 5-lipoxygenase and
cyclooxygenase. 6th Intl. Conference Inflammation Research Association 1992;P112.
43. Kostlan, C.R., W. A. Cetenko, D. T. Connor, R. J. Sorenson, J. C. Sircar, D. A.
Bornemeier, R. D. Dyer, P. J. Kuipers, G. C. Okonkwo, D. J. Schrier, and C. D. Wright.
Structure-activity relationships of thiazolidinone derivatives as dual inhibitors of 5lipoxygenase and cyclooxygenase. 6th Intl. Conference Inflammation Research
Association 1992;P113.
44. Wiles, M.E., J. A. Dykens, and C. D. Wright. Human neutrophil (PMN) oxygen
radical production and the cytoskeleton: an electron paramagnetic resonance (EPR) study.
J. Leuk. Biol. 1992; Suppl 3:40.
45. Dykens, J.A., M. E. Wiles, and C. D. Wright. Cytoskeletal state affects human
neutrophil oxyradical production: an electron spin resonance study. FASEB J.
1993;7:A364.
46. Wiles, M.E., J. A. Dykens, and C. D. Wright. Human neutrophil membrane fluidity
is altered by agents which affect the cytoskeleton. FASEB J. 1993;7:A364.
47. Ferin, M.A., C. Schaechtele, C. Rudolph, and C. D. Wright. Effect of the protein
kinase C inhibitor GF109203X on PMA- and TNF- stimulation of human umbilical vein
endothelial cells and subsequent human neutrophil adhesion. FASEB J. 1993;7:A828.
48. Unangst, P.C., D.T. Connor, W.A. Cetenko, R.J. Sorenson, J.C. Sircar, C.D. Wright,
D.J. Schrier, and R.D. Dyer. Oxazole thiazole and imidazole derivatives of 2,6 di-tertbutylphenol as dual 5 lipoxygenase and cyclooxygenase inhibitors. American Chemical
Society, Division of Medicinal Chemistry, 1993; 206:1-2, MEDI #37.
49. Wright, C. D., P. J. Kuipers, and J. A. Kennedy. Role of phosphatidylcholine
metabolism in the upregulation of beta-2 integrin-dependent neutrophil adhesiveness.
J. Immunol. 1993;150:304A.
50. Schrier, D.J., M.E. Lesch, C.D. Wright, G.C. Okonkwo, M.P. Finkel, and K. Imre.
The antiinflammatory effects of PD 144795, an inhibitor of adhesion ligand expression.
J. Cell. Biochem. 1994;18A:298.
51. Wright, C. D., and J.A. Kennedy. Inhibition of the stimulated upregulation of Mac1-dependent neutrophil adhesiveness by the cell activation inhibitor CI-959. J. Cell.
Biochem. 1994;18C:258.
52. Lesch, M.E., M. Ferin, C. D. Wright, and D. J. Schrier. Protein kinase C involvement
in the expression of PMA- and TNF-alpha-induced ICAM-1 and E-selectin expression.
Inhibition by two isoenzyme specific PKC inhibitors, Gö6850 and Gö6976. J. Cell.
Biochem. 1994, 18D:86.
53. Kramer, J.B., D. H. Boschelli, D. T. Connor, P. J. Kuipers, J. A. Kennedy, C. D.
Wright, D. A. Bornemeier, and R. D. Dyer. Cyclooxygenase and 5-lipoxygenase
inhibitory activity of 2,6 di-t-butyl-phenols linked to 1,3,4-thiadiazoles and 1,3,4oxadiazoles. American Chemical Society, Division of Medicinal Chemistry, March
1994, MEDI #122.
54. Kennedy, J.A., M. E. Wiles, and C. D. Wright. Cytoskeletal modulation does not
affect Mac-1-dependent adhesion of human neutrophils. FASEB J. 1994; 8:A133.
55. Wright, C. D., M. A. Ferin, M. E. Lesch, and D. J. Schrier. Inhibition of neutrophil
adherence to TNF-alpha-stimulated human umbilical vein endothelial cells (HUVECS)
by PD 144795. FASEB J. 1994; 8:A323.
56. Boschelli, D.H., J.D. Kramer, D.T. Connor, M.E. Lesch, SD.J. Schrier, M.A. Ferin,
and C.D. Wright. Inhibition of neutrophil endothelial cell adhesion by 3alkoxybenzo[b]thiophene-2-carboxamides. 24th Natl. Medicinal Chemistry Symposium,
June 1994.
57. Miller, S.R., P.C. Unangst, D.T. Connor, C. R. Kostlan, C.D. Wright, and D. J.
Schrier. Synthesis and evaluation of di-tert-butylpyrimidine ketone and thiazole
derivatives as dual 5-lipoxygenase and cyclooxygenase inhibitors. American Chemical
Society, Division of Medicinal Chemistry, August 1994, MEDI #122.
58. Kostlan, C. D., T.R. Belliotti, D. T. Connor, P. J. Kuipers, M.E. Lesch, D.J. Schrier,
and C.D. Wright, The synthesis of 4,6-di-t-butyl-5-hydroxypyrimidine analogs of 3,5-di-tbutylphenols. American Chemical Society, Division of Medicinal Chemistry, August
1994, MEDI #124.
59. Unangst, P.C., D. T. Connor, G. P. Shrum, T. R. Belliotti, C. R. Kostlan, C. D.
Wright, and D. J. Schrier, Pyrimidine analogs of 2,6-di-tert-butylphenols as dual
cyclooxygenase and 5-lipoxygenase inhibitors. American Chemical Society, Division of
Medicinal Chemistry, August 1994, MEDI #125.
60. Kennedy, J., S. Hartsel, W. Marshall, C. Leidli, D. Lyons, and C. Wright. Effects of
xyloadenosine on activation of human umbilical vein endothelial cells. FASEB J. 1996;
10:A624.
61. Chen, C., M. Breen-Glascock, W. Marshall, J. Kennedy, and C. Wright. Selective
inhibition of E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion
molecule-1 expression by xyloadenosine by an NF-kappa-B-independent mechanisms.
FASEB J. 1996; 10:A624.
62. Tang, W.W., M. Qi, G.Y. Van, D. Lyons, A. Hartman, C. Wright, and M. Kashem.
Recombinant human secretory leukocyte proteinase inhibitor (rhSLPI) ameliorates antiGBM Ab GN. J. Am. Soc. Nephrol. 1996; 7:A2377.
63. Gaudino, J.J., K. Bjergarde, P. Chan-Hui, C.D. Wright, and D.S. Thomson. Synthesis
of novel fluorescently labeled sphingomyelin derivatives useful for sphingomyelinase
assay. American Chemical Society, Division of Medicinal Chemistry, March 1996,
MEDI #227.
64. Havill, A.M., S. Middleton, D. Lyons, and C. Wright. Secretory leukocyte protease
inhibitor (SLPI) prevents the development of airway hyperresponsiveness (AWHR) in
allergen challenged guinea pigs. Am. J. Respir. Crit. Care Med. 1997;155:A654.
65. Boyd, W.A., M. King, H. Garrett, D. Malchenko, R. MacDonald, R. Ghahary, C.
Wright, and D. Lyons. Effect of tryptase instillation on tracheal mucus clearance in dogs.
Am. J. Respir. Crit. Care Med. 1997;155:A779.
66. O’Riordan, T.G., R.A. Otero, Y. Mao, J. Lopez, C. Wright, and W.M. Abraham.
Anti-protease agents or corticosteroids can reverse antigen induced impairment of
mucociliary clearance in ovine airways. Am. J. Respir. Crit. Care Med. 1997;155:A878.
67. Abraham, W.M., R. Forteza, A. Ahmed, A. Cortes, M. Kashem, and C. Wright.
Secretory leukocyte proteinase inhibitor (SLPI) has anti-allergic and anti-inflammatory
activity that may be due to tryptase inhibition. Am. J. Respir. Crit. Care Med.
1997;155:A880.
68. Kennedy, J.A. and C.D. Wright. Effect of mast cell tryptase on bronchial smooth
muscle cell proliferation. FASEB J. 1998;12:A175.
69. Wright, C.D. and J.A. Kennedy. Promotion of mast cell activation by tryptase.
FASEB J. 1998;12:A894.
70. Wright, C.D., A.M. Havill, P.A. Lee, T.G. O’Riordan, M.P. Bevilacqua, and W.M.
Abraham. Secretory leukocyte protease inhibitor prevents allergen-induced pulmonary
responses in animal models of asthma. Collegium Internationale Allergologicum 1998,
A144.
71. King, M., C.D. Wright, J.A. Kennedy, W. Feng, and S.E. Wenzel. Matrix
metalloproteinase profiles in CF sputum. The twelfth annual North American Cystic
Fibrosis Conference 1998, Abstract 398.
72. Ip, A.Y., C.D. Wright, A.M. Havill, M. Benke, J.M. De Long, W.M. Abraham, and
B.S. Chang. Development of spray-dried powder formulations for the pulmonary
delivery of secretory leukocyte protease inhibitor. Annual meeting of the American
Association of Pharmaceutical Scientists 1998. PharmSci suppl. 1998;1:S228.
73. Wright, C.D., S.E. Wenzel, K.K. Brown, G.R. Bernard, B.W. Christman, M. King,
J.A. Kennedy, D.J. Dripps, and M.A. Kashem. Differential expression of matrix
metalloproteinases in disorders of acute and chronic lung injury. Keystone Symposium
1999, Metalloproteases: Chemistry, Biology and Medicine, Abstract 415.
74. Miranda, T., C. Wright, J. Trudeau, H.W. Chu, J.A. Kennedy, M.A. Kashem, and S.
Wenzel. Matrix metalloproteinase 2 and 9 (MMP-2, MMP-9) levels in the airways of
severe asthmatics (SA) compared to moderate (MA) and mild (MIA) asthmatics and
normal controls. Am. J. Respir. Crit. Care Med. 1999; 159:A324.
75. Christman, B., G. Bernard, M. Kashem, J. Kennedy, T. Hagan, P. Price, and C.
Wright. Matrix metalloproteinases (MMP) release into the airspace: difference between
lung injury after bone marrow transplant (BMT) and ARDS. Am. J. Respir. Crit. Care
Med. 1999; 159:A606.
76. Grobmyer, S., P. Barie, C. Nathan, M. Fuortes, E. Lin, S. Lowry, C. Wright, M.
Weyant, L. Hydo, F. Reeves, M. Shiloh, and A. Ding. Secretory leukocyte protease
inhibitor, an inhibitor of neutrophil activation, is elevated in serum in human sepsis and
correlates with severity of organ dysfunction. Fourth International Shock Congress,
1999.
77. Burgess, L., P. Ibrahim, B. Newhouse, R. Rizzi, M. Kashem, A. Hartman, B.
Brandhuber, D. Thomson, C. Wright, and K. Koch. Potent, selective, non-peptidic
inhibitors of human lung tryptase. Mediators Inflamm. 1999; 8 suppl. 1: S105.
78. Kennedy, J.A., S.E. Wenzel, K.K. Brown, G.R. Bernard, B.W. Christman, P.E.
Petrides, M. King, and C.D. Wright. Expression of secretory leukocyte protease inhibitor
in disorders of acute and chronic lung injury. J. Allergy Clin. Immunol. 2000; 105:S306.
79. Burgess, L.E., B.J. Newhouse, P. Ibrahim, J.Rizzi, M.A. Kashem, A.Hartman, B.J.
Brandhuber, C.D. Wright, D.S. Thomson, G.P.A. Vigers, and K. Koch. Potent and
selective inhibitors of human lung tryptase. American Chemical Society, Division of
Medicinal Chemistry, 2000; 219:1-2. MEDI #9.
80. King, M., S.E. Wenzel, J.A. Kennedy, M.A. Kashem, and C.D. Wright. Matrix
metalloproteinases and their tissue inhibitors in cystic fibrosis and COPD sputum. Am. J.
Respir. Crit. Care Med. 2000; 161:A76.
81. Brown, K.K., M.I. Schwarz, T.E. King Jr, J. King, J.A. Kennedy, M.A. Kashem, S.E.
Wenzel, and C.D. Wright. Dysregulation of matrix metalloproteinases (MMPs) in
idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2000; 161:A373.
82. Barrios, V.E., M.A. Jarosinski, and C.D. Wright. Protease-activated receptor 2
mediates hyperresponsiveness in isolated guinea pig bronchi. FASEB J. 2000; 14:A1243.
83. Swenson, S., H. Agadjanian, C.D. Wright, and F.S. Markland. Target sequence
specificity of fibrolase, a snake venom metalloproteinase. 15th International Congress on
Fibrinolysis and Proteolysis. 2000.
84. Wright, C.D., J.A. Kennedy, K.K. Brown, R.J. Falk, and J.C. Jennette. Differential
expression of matrix metalloproteinases in inflammatory and sclerotic glomerular
diseases. Inflammation Research 2000; 49 suppl. 2:S94.
85. Karbon, W., J. Kennedy, A. Lafayette, J. Padagas, C. Wright, R. McGarr, and J.
Andresen. Pharmacological and biochemical properties of Abarelix, a pure GnRH
antagonist. Gynecological Endocrinology 2001; 15 (suppl. 1):40.
86. Barrios, V.E., M.A. Jarosinski and C.D. Wright. Proteinase-activated receptor-2
mediates airway hyperresponsiveness by a neurogenic mechanisms. FASEB J. 2001;
15:A1016.
87. Middleton, S.C., C.D. Wright, and A.M. Havill. Effect of mutant forms of secretory
leukocyte protease inhibitor (SLPI) on guinea pig airway hyperresponsiveness. FASEB J.
2001; 15:A1016.
88. Kennedy, J.A., M.A. Jarosinski and C.D. Wright. Proteinase-activated receptor-2
mediates activation of human umbilical vein endothelial cells. FASEB J. 2001;
15:A1018.
89. Jarosinski, M.A., J.A. Kennedy, B.D. Bennett, T.W. Johnson, B.J. Harding, C-F. Liu,
and C.D. Wright. SLIGRL and Gly4 substituted peptides stimulate IL-8 production in
human umbilical vein endothelial cells via activation of PAR-2 GPCRs. 2nd International
Peptide Symposium in conjunction with the 17th American Peptide Symposium 2001,
A79.
90. Swenson, S., H. Agadjanian, C.D. Wright and F.S. Markland.
Fibrolase cleavage specificity is directly related to in vivo changes in blood pressure
following high dose administration. Thrombosis and Haemostasis (supplement) July
2001; P433.
91. Wright, C.D., F. Fletcher, T. Juan, and K.K. Brown. Comparison of the
pathogenetics of chronic inflammatory airway diseases: idiopathic pulmonary fibrosis vs
emphysema. 5th World Congress on Inflammation 2001, Inflamm. Res. 2001; 50 (suppl.
3):S215.
92. Vliagoftis, H., C. Eberling, J.A. Kennedy, and C.D. Wright. PAR-2 mediated
endothelial cell activation induces leukocyte transmigration through endothelial
monolayers. J. Allergy Clin. Immunol. 2002;109:S167.
93. Wright, D.D., F. Fletcher, T. Juan, and K.K. Brown. Differential gene expression in
idiopathic pulmonary fibrosis. FASEB J. 2002;16:A21.
94. Kennedy, J.A., M.A. Jarosinski and C.D. Wright. Activation of human umbilical
vein endothelial cells by agonists of the proteinase-activated receptor PAR-1 and PAR-2.
FASEB J. 2002;16:A590.
95. Barrios, V.E., M.A. Jarosinski and C.D. Wright. Stimulation of proteinase-activated
receptor-2 (PAR-2) promotes neurotransmitter release from bronchial tissue. FASEB J.
2002; 16: A1147.
96. Kennedy, J.A., M.A. Jarosinski and C.D. Wright. Comparison of signal
transduction pathways associated with proteinase-activated receptor (PAR)-mediated
stimulation of human umbilical vein endothelial cells. FASEB J. 2003; 17:C72.
97. Whoriskey, J.S. and C.D. Wright. Differential Inhibition of CD3- and CD3/CD28stimulated human T lymphocyte responses. Keystone Symposium 2004, Lymphocyte
Activation and Signaling, Abstract 350.
98. Kennedy, J.A. and C.D. Wright. Stimulus-specific inhibition of signal transduction
pathways in human umbilical vein endothelial cells (HUVECs). FASEB J. 2004; 18:A78.
99. Kowski, T.J., N.A. Sealock, S.P. Ragan, P. Benson, J. Sims, T. Born, and C.D.
Wright. Evaluation of cytokine-stimulated nuclear factor B signalling in synoviocytes J.
Leuk. Biol. 2004; suppl.:58.
100. Schooley, K.A., N.A. Sealock, J. Tocker, and C.D. Wright. Cell-specific patterns of
cytokine production stimulated by interleukin-17 (IL-17). FASEB J. 2005; 19:A1418.
101. McDonald, J., M.R. Wright , C.D. Wright, P. Kuehl, M. Duncan, and M. DoyleEisele,. GS-9450- A novel caspase inhibitor provides protection against bleomycin
induced pulmonary fibrosis by inhibition of apoptosis. Am. J. Respir. Crit. Care Med.
2010; 181:A1053.
102. Abraham, W.M., W. R. Baker, and C.D. Wright. Increased effectiveness of GS424020, a mutual prodrug (MPD) containing salmeterol (SAL) and
desisobutrylciclesonide (DESCIC) over its components in the sheep model of asthma.
Am. J. Respir. Crit. Care Med. 2010; 181:A4243.
103. Wright, C.D., E.G. Barrett, J. McDonald, W.M. Abraham, M.R. Wright, T.G.
O’Riordan, and W.R. Baker. The mutual prodrug (MPD) GS-424020 provides improved
activity versus its components in airway models in vivo. Am. J. Respir. Crit. Care Med.
2010; 181:A4246.
104. Wright, M.R, B. Lu, X. Zheng, W.R. Baker, and C.D. Wright. GS-424020Pharmacokinetics of a novel mutual prodrug of salmeterol and desisobutrylciclesonide in
mice, rats, and dogs. Am. J. Respir. Crit. Care Med. 2010; 181:A4247.
105. Barrett, E.G., K. Rudolph, C. Royer, P. Kuehl, B. Lu, M.R. Wright, W.R. Baker and
C.D. Wright. GS-424020- A novel mutual prodrug of salmeterol-desisobutrylciclesonide
attenuates acute bronchoconstriction in the absence of cardiovascular side effects in
ragweed sensitized and naïve dogs. Am. J. Respir. Crit. Care Med. 2010; 181:A4249.
106. Barrett, E.G., M.R. Wright, B. Lu, R. Sorensen, W.R. Baker, and C.D. Wright. GS424020- A novel mutual prodrug of salmeterol-desisobutrylciclesonide attenuates
cigarette smoke-induced lung inflammation in C3H/HeN mice. Am. J. Respir. Crit. Care
Med. 2010; 181:A4432.
107. Tannheimer, S.L., A.C. Haran, J. Velayudhan, E.A. Sorensen, C.D. Wright, and M.
Salmon. Complementary anti-inflammatory interactions of roflumilast and salmeterol in
human primary peripheral blood mononuclear cells. Am. J. Respir. Crit. Care Med.
2010; 181:A5399.
108. Velayudhan, J., S.L. Tannheimer, C.D. Wright, and M. Salmon. The
phosphodiesterase 4 inhibitor, roflumilast, is a potent suppressor of poly (I:C)-induced
cytokine production from air-liquid interface human bronchial epithelial cells. Am. J.
Respir. Crit. Care Med. 2010; 181:A5400.
109. Barrett, E.G., M.R. Wright, B. Lu, W.R. Baker, and C.D. Wright. GS-424020- A
novel mutual prodrug of salmeterol-desisobutrylciclesonide attenuates allergic airway
inflammation in OVA-sensitized BALB/c mice. Am. J. Respir. Crit. Care Med. 2010;
181:A5695.
110. Velayudhan, J., J.H. Therrien, W.R. Baker, J.J. Van Veldhuizen, and C.D. Wright.
In vitro metabolism of GS-424020, a novel mutual prodrug of salmeteroldesisobutrylciclesonide, by air-liquid interface bronchial epithelial cells. Am. J. Respir.
Crit. Care Med. 2010; 181:A6431.
111. Henderson, W.R., X. Ye, Y. T. Tien, and C.D. Wright. Anti-fibrogenic effects of
endothelin-A receptor antagonist Ambrisentan in mouse pulmonary fibrosis model. Eur.
Respir. J. 2010; 36 (suppl 54):E5642.
112. Hayden, P.J., J. Bolmarcich, S. Wilbert, C. Wright, G.R. Jackson, T. Kenney, B.
Baker. Mechanisms Of Goblet Cell Hyperplasia Induced By Simulated Viral Exposure Or
TH2 Cytokines In The EpiAirway-FT™ In Vitro Human Airway Model. Am. J. Respir.
Crit. Care Med. 2011; 183:A2051.
113. Velayudhan, J. and C.D. Wright. The non-thiazolidinedione PPAR- ligand,
GW1929 displays anti-inflammatory activity in poly(I:C)-induced air-liquid interface
human bronchial epithelial cells. Am. J. Respir. Crit. Care Med. 2011; 183:A2827.
114. Tannheimer, S.L., C.D. Wright, and M. Salmon. Roflumilast augments the antiinflammatory and anti-remodeling effects of a beta-2 adrenergic receptor agonist in
human primary lung fibroblasts. Am. J. Respir. Crit. Care Med. 2011; 183:A3590.
115. Liles, J.T., K.M. Joly, K. Wagner, C.D. Wright, and C.F. Plato. Differing effects of
ambrisentan and bosentan on pulmonary fibrosis and lung mechanics following
bleomycin instillation. . Am. J. Respir. Crit. Care Med. 2011; 183:A6042.
116. Henderson, W.R., T.K. Bammler, R.P. Beyer, F.M. Farin, J. Xue, X Ye, Y-T Tien,
and C.D. Wright. Effect of endothelinA and endothelinA/B receptor antagonists on
differential gene expression in lungs with established fibrosis in mouse pulmonary
fibrosis model. Am. J. Respir. Crit. Care Med. 2011; 183:A6043.
117. Kim, M., A.Rudolph, M. Stasiak, J.Van Veldhuizen, W. Baker, and C. D. Wright.
Delivery of Inhaled Corticosteroid (ICS) and Long Acting Beta Agonist (LABA) via
mutual prodrug strategy for the treatment of pulmonary inflammation and
bronchoconstriction. American Chemical Society, Division of Medicinal Chemistry,
2011.
118. Tarran, R., C. Davies, J. Liu, A, Yeung, C. D. Wright, and S. Wilbert. Azithromycin
and the non-antibacterial macrolide GS-459755 protect human bronchial epithelial cells
from elastase-induced dehydration. Am. J. Respir. Crit. Care Med. 2012.
119. Wilbert, S., J.R. Sabater, T. C. Clarke, J. Liu, A. Yeung, C. D. Wright, and W. M.
Abraham. Azithromycin and the non-antibacterial macrolide GS-459755 prevent
neutrophil elastase-induced mucociliary dysfunction in sheep. Am. J. Respir. Crit. Care
Med. 2012.
120. McDonald, J, M. Doyle-Eisele, P. Kuehl, K. Rudolph, E.G. Barrett, CD Wright,
and M. Salmon. Evaluation of the bronchodilator and anti-inflammatory pharmacology
of the bifunctional 2 agonist and PDE4 inhibitor GS-5759 in non-human primates. Am.
J. Respir. Crit. Care Med. 2012.
121. Barrett, E.G., K. Rudolph, C. Royer, P, Kuehl, K.D. Bruce, E.A. Sorensen, C.D.
Wright and M. Salmon. GS-5759, a novel bi-functional phosphodiesterase 4 inhibitor and
long-acting 2-adrenoceptor agonist attenuates acute bronchoconstriction in the absence
of cardiovascular side-effects in ragweed sensitized and naïve dogs. Am. J. Respir. Crit.
Care Med. 2012.
122. Cui, Z.-H., T. T. Gentzler, C. D. Wright, and M. Salmon. GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long-acting 2-adrenoceptor agonist, in vivo
characterization of the bronchodilator pharmacology and safety in guinea pigs. Am. J.
Respir. Crit. Care Med. 2012.
123. Wilson, S.M., T. Joshi, C. D. Wright, S. L. Tannheimer, M. Salmon, R. Newton,
and M.A. Giembycz. GS-5759, a novel bi-functional phosphodiesterase 4 inhibitor and
long-acting 2-adrenoceptor agonist, inhibits CXCL9 and CXCL10 release from human
airway epithelial cells. Am. J. Respir. Crit. Care Med. 2012.
124. Joshi, T., S,M, Wilson,, S.L. Tannheimer, C.D. Wright, M. Salmon, R. Newton,
and M.A. Giembycz. GS-5759, a novel bi-functional phosphodiesterase 4 inhibitor and
long-acting 2-adrenoceptor agonist, augments GRE-dependent transcription in human
airway epithelial cells. Am. J. Respir. Crit. Care Med. 2012.
125. Sorensen, E.A., S. L. Tannheimer, A.C. Haran, C. D. Wright, and M. Salmon.
GS-5759, a novel bi-functional phosphodiesterase 4 inhibitor and long-acting 2adrenoceptor agonist has potent anti-inflammatory activity in human monocytes and
neutrophils. Am. J. Respir. Crit. Care Med. 2012.
126. Tannheimer, S.L., C. D. Wright, and M. Salmon. GS-5759, a novel bi-functional
phosphodiesterase 4 inhibitor and long-acting 2-adrenoceptor agonist has antiinflammatory and anti-remodeling activity in human lung fibroblasts. Am. J. Respir. Crit.
Care Med. 2012.